{"id":31882,"date":"2024-06-29T11:34:19","date_gmt":"2024-06-29T15:34:19","guid":{"rendered":"https:\/\/einvestingforbeginners.com\/?p=31882"},"modified":"2024-06-29T11:34:23","modified_gmt":"2024-06-29T15:34:23","slug":"publicly-traded-life-sciences-industry-report-spring-2024-results-schil","status":"publish","type":"post","link":"https:\/\/einvestingforbeginners.com\/publicly-traded-life-sciences-industry-report-spring-2024-results-schil\/","title":{"rendered":"Publicly Traded Life Sciences Industry Report: Spring 2024 Results"},"content":{"rendered":"\n<p>Latest Spring earnings showed that the Top 5 Publicly Traded Life Science tool companies by market cap decreased total revenues in the high to low single digits YOY in the January \u2013 March Quarter, according to their Latest Earnings Releases.<\/p>\n\n\n\n<p>Of the publicly traded Life Science tool companies who released earnings results, the following top 5 companies decreased revenues&nbsp;<strong>-8.20%<\/strong>&nbsp;YOY on average: Thermo Fisher, Danaher, Agilent, Sartorius Stedim Biotech, and West Pharmaceuticals.<\/p>\n\n\n\n<figure class=\"wp-block-image alignwide size-large\"><a href=\"https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/The-Top-5-Life-Science-tool-companies-by-YOY-Revenues-_-1.png?strip=all&lossy=1&w=2560&ssl=1\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"560\" src=\"https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/The-Top-5-Life-Science-tool-companies-by-YOY-Revenues-_-1-1024x560.png?strip=all&lossy=1&ssl=1\" alt=\"bar chart of top 5 life science tool companies by yoy revenues spring 2024\" class=\"wp-image-31913\" srcset=\"https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/The-Top-5-Life-Science-tool-companies-by-YOY-Revenues-_-1-1024x560.png?strip=all&amp;lossy=1&amp;ssl=1 1024w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/The-Top-5-Life-Science-tool-companies-by-YOY-Revenues-_-1-300x164.png?strip=all&amp;lossy=1&amp;ssl=1 300w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/The-Top-5-Life-Science-tool-companies-by-YOY-Revenues-_-1-768x420.png?strip=all&amp;lossy=1&amp;ssl=1 768w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/The-Top-5-Life-Science-tool-companies-by-YOY-Revenues-_-1.png?strip=all&amp;lossy=1&amp;ssl=1 1478w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/The-Top-5-Life-Science-tool-companies-by-YOY-Revenues-_-1.png?strip=all&amp;lossy=1&amp;w=160&amp;ssl=1 160w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/The-Top-5-Life-Science-tool-companies-by-YOY-Revenues-_-1.png?strip=all&amp;lossy=1&amp;w=480&amp;ssl=1 480w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/The-Top-5-Life-Science-tool-companies-by-YOY-Revenues-_-1.png?strip=all&amp;lossy=1&amp;w=640&amp;ssl=1 640w\" sizes=\"(max-width: 1500px) 100vw, 1500px\" \/><\/a><figcaption class=\"wp-element-caption\"><em>Note: Danaher\u2019s March 2023 revenue exclude Veralto<\/em><\/figcaption><\/figure>\n\n\n\n<p><\/p>\n\n\n\n<p>Danaher stood out with the least decrease in revenues at&nbsp;<strong>-2.6%<\/strong>&nbsp;followed by West Pharmaceutical with a decrease of&nbsp;<strong>-3.00%<\/strong>&nbsp;YOY.<\/p>\n\n\n\n<p>The following sections are covered in this report [<strong>Click to Skip Ahead<\/strong>]:<\/p>\n\n\n\n<ul>\n<li><strong><a href=\"#Mkt-share\">Biggest Publicly Traded Life Science Tools by Market Share<\/a><\/strong><\/li>\n\n\n\n<li><strong><a href=\"#Rev-growth\">Top Life Science Tools Provider by Revenue Growth<\/a><\/strong><\/li>\n\n\n\n<li><strong><a href=\"#EPS-growth\">Top Life Science Tools Provider by Earnings (EPS) Growth<\/a><\/strong><\/li>\n<\/ul>\n\n\n\n<p>Company revenues, earnings, and stock forecasts covered:<\/p>\n\n\n\n<ul>\n<li><strong><a href=\"#TMO-fore\">Thermo Fisher (TMO) Stock Forecast<\/a><\/strong><\/li>\n\n\n\n<li><strong><a href=\"#DHR-fore\">Danaher (DHR) Stock Forecast<\/a><\/strong><\/li>\n\n\n\n<li><strong><a href=\"#AGI-fore\">Agilent (A) Stock Forecast<\/a><\/strong><\/li>\n\n\n\n<li><strong><a href=\"#DIM-fore\">Sartorius Stedim Biotech S.A. (DIM) Stock Forecast<\/a><\/strong><\/li>\n\n\n\n<li><strong><a href=\"#WST-fore\">West Pharmaceutical Services (WST) Stock Forecast<\/a><\/strong><\/li>\n<\/ul>\n\n\n\n<p>The list below only includes the top 5 Life science tools companies by market capitalization. The next section will include all &gt;$5B market cap publicly traded life science companies.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>March 2023<\/strong><\/td><td><strong>March 2024<\/strong><\/td><td><strong>YOY<\/strong><\/td><\/tr><tr><td><em>Thermo Fisher<\/em><\/td><td>$10,687<\/td><td>$10,345<\/td><td>-3.40%<\/td><\/tr><tr><td><em>Danaher<\/em><\/td><td>$5,949<\/td><td>$5,796<\/td><td>-2.60%<\/td><\/tr><tr><td><em>Agilent<\/em><\/td><td>$1,717<\/td><td>$1,573<\/td><td>-8.40%<\/td><\/tr><tr><td><em>Sartorius Stedim Biotech<\/em><\/td><td>$787<\/td><td>$718<\/td><td>-8.20%<\/td><\/tr><tr><td><em>West Pharmaceutical<\/em><\/td><td>$716<\/td><td>$695<\/td><td>-3.00%<\/td><\/tr><\/tbody><\/table><figcaption class=\"wp-element-caption\">*<em>In millions<\/em>;&nbsp;<em>Danaher\u2019s March 2023 revenues excludes Veralto<\/em><\/figcaption><\/figure>\n\n\n\n<p><em>Thermo Fisher<\/em>&nbsp;reported a <strong>-3.40<\/strong>% decrease YoY revenue while organic revenue declined <strong>-4%<\/strong>. However, revenues were a sequential improvement in performance over Q4 2023. In their Diagnostics and healthcare, revenue declined in high single digits. Management noted the reported growth is still impacted by the runoff of COVID-19 testing-related revenue.<\/p>\n\n\n\n<p><em>Danaher<\/em>\u00a0saw revenue decline by\u00a0<strong>-2.60<\/strong>%\u00a0YoY, while non-GAAP core revenue decreased by <strong>-4.0<\/strong>%. However, management was pleased to see improving order trends in their bioprocessing business and believed they continue gaining market share in our molecular diagnostic business at Cepheid.<\/p>\n\n\n\n<p><em>Agilent<\/em>&nbsp;had a&nbsp;<strong>-8.40%<\/strong>&nbsp;YoY decrease in revenue last quarter with&nbsp;<strong>-7.40%<\/strong>&nbsp;decrease in core revenue growth. Its Life Sciences and Applied Markets Group reported a decline of <strong>-14.0%<\/strong> in revenues. Management sees the market improving albeit at a slower pace than anticipated.<\/p>\n\n\n\n<p><em>Sartorius Stedim Biotech<\/em>&nbsp;showed a &#8211;<strong>7.60<\/strong>% YoY decrease in the latest quarterly revenue (in constant currencies), attributing the decline to continued reluctance in investments particularly in China and to some extent in Europe which dampened the order intake of their equipment business.<\/p>\n\n\n\n<p><em>West Pharmaceutical Services<\/em>\u00a0saw both revenue and organic net sales decrease by\u00a0<strong>-3.0<\/strong>%. However, management is expecting better second-half revenue growth as order trends and customer inventory reduction timings reinforce this.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Key Takeaway<\/strong><\/h2>\n\n\n\n<p>The recent quarter, although still showed a decline in the overall revenues of publicly traded life science tools companies, was better than anticipated. Sequential orders and book-to-bill ratios of companies improved, with some saying the inventory destocking was largely behind now. Funding in bioprocessing also showed signs of improvement with it back now to 2019 levels.<\/p>\n\n\n\n<p>Meanwhile, China remains soft, with low activity levels and demand remaining weak.<\/p>\n\n\n\n<p class=\"anchor\" id=\"Mkt-share\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Biggest Publicly Traded Life Science Tools by Market Share<\/h2>\n\n\n\n<p>The chart below shows the list of publicly traded life science tool providers with market caps of &gt;$5B as of June 2024.<\/p>\n\n\n\n<figure class=\"wp-block-image alignwide size-large\"><a href=\"https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Publicly-Traded-Life-Science-Tools-Companies-Market-share-Revenues-TTM-8.png?strip=all&lossy=1&w=2560&ssl=1\"><img decoding=\"async\" width=\"1024\" height=\"633\" src=\"https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Publicly-Traded-Life-Science-Tools-Companies-Market-share-Revenues-TTM-8-1024x633.png?strip=all&lossy=1&ssl=1\" alt=\"pie chart of top publicly traded life science tool companies by market share revenues spring 2024\" class=\"wp-image-31925\" srcset=\"https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Publicly-Traded-Life-Science-Tools-Companies-Market-share-Revenues-TTM-8-1024x633.png?strip=all&amp;lossy=1&amp;ssl=1 1024w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Publicly-Traded-Life-Science-Tools-Companies-Market-share-Revenues-TTM-8-300x185.png?strip=all&amp;lossy=1&amp;ssl=1 300w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Publicly-Traded-Life-Science-Tools-Companies-Market-share-Revenues-TTM-8-768x475.png?strip=all&amp;lossy=1&amp;ssl=1 768w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Publicly-Traded-Life-Science-Tools-Companies-Market-share-Revenues-TTM-8.png?strip=all&amp;lossy=1&amp;ssl=1 1270w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Publicly-Traded-Life-Science-Tools-Companies-Market-share-Revenues-TTM-8.png?strip=all&amp;lossy=1&amp;w=160&amp;ssl=1 160w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Publicly-Traded-Life-Science-Tools-Companies-Market-share-Revenues-TTM-8.png?strip=all&amp;lossy=1&amp;w=480&amp;ssl=1 480w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Publicly-Traded-Life-Science-Tools-Companies-Market-share-Revenues-TTM-8.png?strip=all&amp;lossy=1&amp;w=640&amp;ssl=1 640w\" sizes=\"(max-width: 1500px) 100vw, 1500px\" \/><\/a><figcaption class=\"wp-element-caption\"><em>*In USD<\/em><\/figcaption><\/figure>\n\n\n\n<p><\/p>\n\n\n\n<p>Leading the group is Thermo Fisher with roughly 49.3% market share, followed by Danaher with 27.6%, and trailing behind is Avantor with 8.0% of Trailing Twelve Months (TTM) revenue share of all publicly traded life science tools providers.<\/p>\n\n\n\n<figure class=\"wp-block-table is-style-stripes\"><table><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>Revenues (TTM in Thousands)<\/strong><\/td><td><strong>Mkt Share<\/strong><\/td><\/tr><tr><td>Thermo Fisher<\/td><td>$42,492,000<\/td><td>49.3%<\/td><\/tr><tr><td>Danaher<\/td><td>$23,737,000<\/td><td>27.6%<\/td><\/tr><tr><td>Avantor<\/td><td>$6,866,700<\/td><td>8.0%<\/td><\/tr><tr><td>Agilent Technologies<\/td><td>$6,591,000<\/td><td>7.7%<\/td><\/tr><tr><td>Sartorius Stedim Biotech<\/td><td>$2,931,153<\/td><td>3.4%<\/td><\/tr><tr><td>West Pharmaceutical<\/td><td>$2,928,600<\/td><td>3.4%<\/td><\/tr><tr><td>Repligen Corp<\/td><td>$607,450<\/td><td>0.7%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"anchor\" id=\"Rev-growth\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Top Life Science Tools Provider by Revenue Growth<\/h2>\n\n\n\n<p>Repligen Corp.&#8217;s revenues increased <strong>11.95%<\/strong> faster than its peers in the life science tools industry in the previous three fiscal years.<\/p>\n\n\n\n<p>West Pharmaceuticals, on the other hand, is ahead in boosting its YOY growth, with the only company growing its revenue by&nbsp;<strong>1.56%<\/strong>&nbsp;from 2023-2024.<\/p>\n\n\n\n<figure class=\"wp-block-image alignwide size-large\"><a href=\"https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Top-Life-Science-Tools-provider-by-Revenue-Growth-5.png?strip=all&lossy=1&w=2560&ssl=1\"><img decoding=\"async\" width=\"1024\" height=\"387\" src=\"https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Top-Life-Science-Tools-provider-by-Revenue-Growth-5-1024x387.png?strip=all&lossy=1&ssl=1\" alt=\"bar chart of top publicly traded life science tool companies by revenue growth spring 2024\" class=\"wp-image-31927\" srcset=\"https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Top-Life-Science-Tools-provider-by-Revenue-Growth-5-1024x387.png?strip=all&amp;lossy=1&amp;ssl=1 1024w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Top-Life-Science-Tools-provider-by-Revenue-Growth-5-300x113.png?strip=all&amp;lossy=1&amp;ssl=1 300w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Top-Life-Science-Tools-provider-by-Revenue-Growth-5-768x290.png?strip=all&amp;lossy=1&amp;ssl=1 768w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Top-Life-Science-Tools-provider-by-Revenue-Growth-5-1536x580.png?strip=all&amp;lossy=1&amp;ssl=1 1536w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Top-Life-Science-Tools-provider-by-Revenue-Growth-5.png?strip=all&amp;lossy=1&amp;ssl=1 1759w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Top-Life-Science-Tools-provider-by-Revenue-Growth-5.png?strip=all&amp;lossy=1&amp;w=160&amp;ssl=1 160w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Top-Life-Science-Tools-provider-by-Revenue-Growth-5.png?strip=all&amp;lossy=1&amp;w=480&amp;ssl=1 480w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Top-Life-Science-Tools-provider-by-Revenue-Growth-5.png?strip=all&amp;lossy=1&amp;w=640&amp;ssl=1 640w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Top-Life-Science-Tools-provider-by-Revenue-Growth-5.png?strip=all&amp;lossy=1&amp;w=1600&amp;ssl=1 1600w\" sizes=\"(max-width: 1500px) 100vw, 1500px\" \/><\/a><\/figure>\n\n\n\n<p><\/p>\n\n\n\n<p>Sartorius Stedim Biotech takes the second spot in 3yr revenue CAGR with <strong>8.22<\/strong>% while the other two Life Science companies, West Pharmaceutical and Thermo Fisher, trail behind with <strong>7.98<\/strong>% and <strong>5.79<\/strong>% 3yr revenue CAGRs, respectively.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>3yr CAGR<\/strong><\/td><td><strong>1yr CAGR YOY<\/strong><\/td><\/tr><tr><td>Repligen Corp<\/td><td>11.95%<\/td><td>-21.90%<\/td><\/tr><tr><td>Sartorius Stedim Biotech S.A.<\/td><td>8.22%<\/td><td>-19.07%<\/td><\/tr><tr><td>West Pharmaceutical Services<\/td><td>7.98%<\/td><td>1.56%<\/td><\/tr><tr><td>Thermo Fisher<\/td><td>5.79%<\/td><td>-3.00%<\/td><\/tr><tr><td>Agilent Technologies<\/td><td>6.79%<\/td><td>-2.81%<\/td><\/tr><tr><td>Avantor<\/td><td>1.02%<\/td><td>-6.48%<\/td><\/tr><tr><td>Danaher<\/td><td>-1.45%<\/td><td>-4.69%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Key Takeaway<\/strong><\/h3>\n\n\n\n<p>The decline in revenue growth of publicly traded life science tools still continued in recent quarter albeit softer than anticipated. As most companies pointed out, the bioprocessing industry is seeing a slow and gradual recovery through the first half of the year while things will get better in the second half.<\/p>\n\n\n\n<p class=\"anchor\" id=\"EPS-growth\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Top Life Science Tools Provider by Earnings (EPS) Growth<\/h2>\n\n\n\n<p>In the last three fiscal years, Agilent took the spot and saw the highest 3 year annual compounded growth rate of&nbsp;<strong>12.16%<\/strong>&nbsp;in earnings per share.<\/p>\n\n\n\n<p>The graph below shows that the EPS growth of publicly traded life science tool providers continued to decline, with only the top 3 recording high single-digit EPS growth over the past three years.<\/p>\n\n\n\n<figure class=\"wp-block-image alignwide size-large\"><a href=\"https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Top-Life-Science-Tools-by-Earnings-EPS-Growth-3.png?strip=all&lossy=1&w=2560&ssl=1\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"545\" src=\"https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Top-Life-Science-Tools-by-Earnings-EPS-Growth-3-1024x545.png?strip=all&lossy=1&ssl=1\" alt=\"bar chart of top publicly traded life science tool companies by earnings per share (EPS) growth spring 2024\" class=\"wp-image-31934\" srcset=\"https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Top-Life-Science-Tools-by-Earnings-EPS-Growth-3-1024x545.png?strip=all&amp;lossy=1&amp;ssl=1 1024w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Top-Life-Science-Tools-by-Earnings-EPS-Growth-3-300x160.png?strip=all&amp;lossy=1&amp;ssl=1 300w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Top-Life-Science-Tools-by-Earnings-EPS-Growth-3-768x409.png?strip=all&amp;lossy=1&amp;ssl=1 768w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Top-Life-Science-Tools-by-Earnings-EPS-Growth-3-1536x817.png?strip=all&amp;lossy=1&amp;ssl=1 1536w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Top-Life-Science-Tools-by-Earnings-EPS-Growth-3.png?strip=all&amp;lossy=1&amp;ssl=1 1780w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Top-Life-Science-Tools-by-Earnings-EPS-Growth-3.png?strip=all&amp;lossy=1&amp;w=160&amp;ssl=1 160w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Top-Life-Science-Tools-by-Earnings-EPS-Growth-3.png?strip=all&amp;lossy=1&amp;w=480&amp;ssl=1 480w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Top-Life-Science-Tools-by-Earnings-EPS-Growth-3.png?strip=all&amp;lossy=1&amp;w=640&amp;ssl=1 640w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/06\/Top-Life-Science-Tools-by-Earnings-EPS-Growth-3.png?strip=all&amp;lossy=1&amp;w=1600&amp;ssl=1 1600w\" sizes=\"(max-width: 1500px) 100vw, 1500px\" \/><\/a><\/figure>\n\n\n\n<p><\/p>\n\n\n\n<p>Meanwhile, West Pharmaceutical still had the highest 1-year EPS YOY growth rate among the list of&nbsp;<strong>4.06%<\/strong>.<\/p>\n\n\n\n<p>The list\u2019s highest 3-year EPS CAGR companies include Agilent at&nbsp;<strong>12.16%<\/strong>, West Pharmaceutical at&nbsp;<strong>10.85%,<\/strong>&nbsp;and Avantor at&nbsp;<strong>9.22%.<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>3yr EPS CAGR<\/strong><\/td><td><strong>1yr EPS YOY Growth<\/strong><\/td><\/tr><tr><td>Agilent<\/td><td>12.16%<\/td><td>-7.15%<\/td><\/tr><tr><td>West Pharmaceutical Services<\/td><td>10.85%<\/td><td>4.06%<\/td><\/tr><tr><td>Avantor<\/td><td>9.22%<\/td><td>-58.28%<\/td><\/tr><tr><td>Danaher<\/td><td>-2.51%<\/td><td>-36.49%<\/td><\/tr><tr><td>Thermo Fisher<\/td><td>-7.76%<\/td><td>1.64%<\/td><\/tr><tr><td>Sartorius Stedim Biotech S.A.<\/td><td>-14.15%<\/td><td>-64.99%<\/td><\/tr><tr><td>Repligen Corp<\/td><td>-43.35%<\/td><td>-91.02%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Life Science Tools Companies Revenue, Earnings and Stock Forecast (Quarter ending March 2024)<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>YOY EPS Forecast<\/strong><\/td><\/tr><tr><td>Thermo Fisher<\/td><td>-0.49%<\/td><\/tr><tr><td>Danaher<\/td><td>-23.22%<\/td><\/tr><tr><td>Agilent<\/td><td>-11.94%<\/td><\/tr><tr><td>Sartorius Stedim Biotech S.A.<\/td><td>-24.62%<\/td><\/tr><tr><td>West Pharmaceutical Services<\/td><td>-18.07%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"anchor\" id=\"TMO-fore\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Thermo Fisher (TMO) Revenue, Earnings, and Stock Forecast<\/strong><\/h2>\n\n\n\n<p>Thermo Fisher\u2019s revenue over the latest Trailing Twelve Month period was&nbsp;<strong>$42.5 billion<\/strong>. Thermo Fisher\u2019s earnings (Net Income) over the latest Trailing Twelve Month period was&nbsp;<strong>$6.0 billion<\/strong>.<\/p>\n\n\n\n<p>The Wall Street consensus for Thermo Fisher\u2019s EPS (earnings per share) projection for the next quarter is&nbsp;<strong>$5.12<\/strong>. The company\u2019s TTM (trailing twelve months) Earnings Per Share was&nbsp;<strong>$15.70<\/strong>&nbsp;as of the quarter ending March 30, 2024.<\/p>\n\n\n\n<p>Thermo Fisher is expected to see a contraction in earnings per share of\u00a0\u2013<strong>0.49%<\/strong>\u00a0YOY\u00a0in the next quarter based on the consensus of stock market analyst forecasts.<\/p>\n\n\n\n<p class=\"anchor\" id=\"DHR-fore\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Danaher (DHR) Revenue, Earnings, and Stock Forecast<\/strong><\/h2>\n\n\n\n<p>Danaher\u2019s revenue over the latest Trailing Twelve Month period was&nbsp;<strong>$23.7 billion<\/strong>. Danaher\u2019s earnings (Net Income) over the latest Trailing Twelve Month period was&nbsp;<strong>$4.4 billion<\/strong>.<\/p>\n\n\n\n<p>The Wall Street consensus for Danaher\u2019s EPS (earnings per share) projection for the next quarter is&nbsp;<strong>$1.57<\/strong> The company\u2019s TTM (trailing twelve months) Earnings Per Share was&nbsp;<strong>$6.0<\/strong>&nbsp;as of the quarter ending March 30, 2024.<\/p>\n\n\n\n<p>Danaher is expected to see a contraction in earnings per share of\u00a0<strong>-23.22%<\/strong>\u00a0YOY\u00a0in the next quarter based on the consensus of stock market analyst forecasts.<\/p>\n\n\n\n<p class=\"anchor\" id=\"AGI-fore\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Agilent Technologies (A)&nbsp;Revenue, Earnings, and Stock Forecast<\/strong><\/h2>\n\n\n\n<p>Agilent\u2019s revenue over the latest Trailing Twelve Month period was&nbsp;<strong>$6.6 billion<\/strong>. Agilent\u2019s earnings (Net Income) over the latest Trailing Twelve Month period was&nbsp;<strong>$1.20 billion<\/strong>.<\/p>\n\n\n\n<p>The Wall Street consensus for Agilent\u2019s EPS (earnings per share) projection for the next quarter is&nbsp;<strong>$1.26<\/strong>. The company\u2019s TTM (trailing twelve months) Earnings Per Share was&nbsp;<strong>$4.20<\/strong>&nbsp;as of the quarter ending March 30, 2024.<\/p>\n\n\n\n<p>Agilent is expected to see a contraction in earnings per share of\u00a0<strong>-11.94<\/strong>%\u00a0YOY\u00a0in the next quarter based on the consensus of stock market analyst forecasts.<\/p>\n\n\n\n<p class=\"anchor\" id=\"DIM-fore\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Sartorius Stedim Biotech S.A. (DIM) Revenue, Earnings, and Stock Forecast<\/strong><\/h2>\n\n\n\n<p>Sartorius Stedim\u2019s revenue over the latest Trailing Twelve Month period was&nbsp;<strong>$2.9 billion<\/strong>. Sartorius Stedim\u2019s earnings (Net Income) over the latest Trailing Twelve Month period was&nbsp;<strong>$0.3 billion<\/strong>.<\/p>\n\n\n\n<p>The Wall Street consensus for Sartorius Stedim\u2019s EPS (earnings per share) projection for the next quarter is&nbsp;<strong>$1.06<\/strong>. The company\u2019s TTM (trailing twelve months) Earnings Per Share was&nbsp;<strong>$2.90<\/strong>&nbsp;as of the quarter ending March 30, 2024.<\/p>\n\n\n\n<p>Sartorius Stedim is expected to see a contraction in earnings per share of\u00a0&#8211;<strong>24.62<\/strong>%\u00a0YOY\u00a0in the next quarter based on the consensus of stock market analyst forecasts.<\/p>\n\n\n\n<p class=\"anchor\" id=\"WST-fore\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>West Pharmaceutical Services (WST) Revenue, Earnings, and Stock Forecast<\/strong><\/h2>\n\n\n\n<p>West Pharmaceutical Services\u2019 revenue over the latest Trailing Twelve Month period was&nbsp;<strong>$2.93 billion<\/strong>. West Pharmaceutical Services\u2019 earnings (Net Income) over the latest Trailing Twelve Month period was&nbsp;<strong>$0.57 billion<\/strong>.<\/p>\n\n\n\n<p>The Wall Street consensus for West Pharmaceutical Services\u2019 EPS (earnings per share) projection for the next quarter is&nbsp;<strong>$1.73<\/strong>. The company\u2019s TTM (trailing twelve months) Earnings Per Share was&nbsp;<strong>$7.70<\/strong>&nbsp;as of the quarter ending March 30, 2024.<\/p>\n\n\n\n<p>West Pharmaceutical Services is expected to see a contraction in earnings per share of&nbsp;<strong>-18.07%<\/strong>&nbsp;YOY&nbsp;in the next quarter based on the consensus of stock market analyst forecasts.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Methodology<\/strong><\/h3>\n\n\n\n<p>All data mentioned here in this article was sourced from publicly available filings and releases, and processed by investment newsletter provider Sather Research, LLC.<\/p>\n\n\n\n<p>Stock forecasts and analyst consensus EPS growth estimates were sourced from data provided by&nbsp;<a href=\"https:\/\/seekingalpha.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Seeking Alpha<\/a>.<\/p>\n\n\n\n<p>Contact Seoshin Chil at\u00a0<a href=\"mailto:chil@einvestingforbeginners.com\" target=\"_blank\" rel=\"noreferrer noopener\">chil@einvestingforbeginners.com<\/a>\u00a0for any further commentary, concerns, questions, or feedback. Alternatively, you can get in touch with the company during business hours through our\u00a0<a href=\"https:\/\/einvestingforbeginners.com\/contact\/\" target=\"_blank\" rel=\"noreferrer noopener\">contact page<\/a>, or call 888-978-1348 from Monday \u2013 Friday; 9AM EST \u2013 5:00 PM EST.<\/p>\n\n\n\n<div class=\"wp-block-columns Has-Border-Rounded has-background is-layout-flex wp-container-core-columns-is-layout-1 wp-block-columns-is-layout-flex\" style=\"background-color:#bdfed2\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<div style=\"height:27px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<figure class=\"wp-block-image size-full has-custom-border is-style-rounded\"><img loading=\"lazy\" decoding=\"async\" width=\"1735\" height=\"1920\" src=\"https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/03\/DSC00737-1.jpg?strip=all&lossy=1&ssl=1\" alt=\"\" class=\"wp-image-30727\" style=\"border-width:7px;border-radius:26px\" srcset=\"https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/03\/DSC00737-1.jpg?strip=all&amp;lossy=1&amp;ssl=1 1735w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/03\/DSC00737-1-271x300.jpg?strip=all&amp;lossy=1&amp;ssl=1 271w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/03\/DSC00737-1-925x1024.jpg?strip=all&amp;lossy=1&amp;ssl=1 925w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/03\/DSC00737-1-768x850.jpg?strip=all&amp;lossy=1&amp;ssl=1 768w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/03\/DSC00737-1-1388x1536.jpg?strip=all&amp;lossy=1&amp;ssl=1 1388w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/03\/DSC00737-1.jpg?strip=all&amp;lossy=1&amp;w=160&amp;ssl=1 160w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/03\/DSC00737-1.jpg?strip=all&amp;lossy=1&amp;w=480&amp;ssl=1 480w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/03\/DSC00737-1.jpg?strip=all&amp;lossy=1&amp;w=640&amp;ssl=1 640w, https:\/\/eor7ztmv4pb.exactdn.com\/wp-content\/uploads\/2024\/03\/DSC00737-1.jpg?strip=all&amp;lossy=1&amp;w=1600&amp;ssl=1 1600w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<h2 class=\"wp-block-heading has-text-align-center\">Seoshin Chil<\/h2>\n\n\n\n<p class=\"has-text-align-center\">Seoshin is an active sailor in offshore windfarm vessels but has a passion for studying great businesses and investing in them. Being always at sea does not stop him from doing so!<\/p>\n\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-1 wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-foreground-color has-text-color has-background wp-element-button\" href=\"https:\/\/open.spotify.com\/show\/6Hdk9ZaDt3Hk4RfpapMnkU\" style=\"background-color:#3ce474\" target=\"_blank\" rel=\"noreferrer noopener\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-black-color\">Seafarer Investor Podcast<\/mark><\/a><\/div>\n<\/div>\n\n\n\n<div style=\"height:11px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<ul class=\"wp-block-social-links has-icon-color is-style-logos-only is-content-justification-center is-layout-flex wp-container-core-social-links-is-layout-1 wp-block-social-links-is-layout-flex\"><li style=\"color: #000000; \" class=\"wp-social-link wp-social-link-twitter has-black-color wp-block-social-link\"><a rel=\"noopener nofollow\" target=\"_blank\" href=\"https:\/\/twitter.com\/TSFInvestor\" class=\"wp-block-social-link-anchor\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M22.23,5.924c-0.736,0.326-1.527,0.547-2.357,0.646c0.847-0.508,1.498-1.312,1.804-2.27 c-0.793,0.47-1.671,0.812-2.606,0.996C18.324,4.498,17.257,4,16.077,4c-2.266,0-4.103,1.837-4.103,4.103 c0,0.322,0.036,0.635,0.106,0.935C8.67,8.867,5.647,7.234,3.623,4.751C3.27,5.357,3.067,6.062,3.067,6.814 c0,1.424,0.724,2.679,1.825,3.415c-0.673-0.021-1.305-0.206-1.859-0.513c0,0.017,0,0.034,0,0.052c0,1.988,1.414,3.647,3.292,4.023 c-0.344,0.094-0.707,0.144-1.081,0.144c-0.264,0-0.521-0.026-0.772-0.074c0.522,1.63,2.038,2.816,3.833,2.85 c-1.404,1.1-3.174,1.756-5.096,1.756c-0.331,0-0.658-0.019-0.979-0.057c1.816,1.164,3.973,1.843,6.29,1.843 c7.547,0,11.675-6.252,11.675-11.675c0-0.178-0.004-0.355-0.012-0.531C20.985,7.47,21.68,6.747,22.23,5.924z\"><\/path><\/svg><span class=\"wp-block-social-link-label screen-reader-text\">Twitter<\/span><\/a><\/li><\/ul>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Latest Spring earnings showed that the Top 5 Publicly Traded Life Science tool companies by market cap decreased total revenues in the high to low single digits YOY in the January \u2013 March Quarter, according to their Latest Earnings Releases. Of the publicly traded Life Science tool companies who released earnings results, the following top [&hellip;]<\/p>\n","protected":false},"author":44,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"footnotes":""},"categories":[5954,5970,5962,931],"tags":[],"yst_prominent_words":[],"_links":{"self":[{"href":"https:\/\/einvestingforbeginners.com\/wp-json\/wp\/v2\/posts\/31882"}],"collection":[{"href":"https:\/\/einvestingforbeginners.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/einvestingforbeginners.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/einvestingforbeginners.com\/wp-json\/wp\/v2\/users\/44"}],"replies":[{"embeddable":true,"href":"https:\/\/einvestingforbeginners.com\/wp-json\/wp\/v2\/comments?post=31882"}],"version-history":[{"count":17,"href":"https:\/\/einvestingforbeginners.com\/wp-json\/wp\/v2\/posts\/31882\/revisions"}],"predecessor-version":[{"id":31958,"href":"https:\/\/einvestingforbeginners.com\/wp-json\/wp\/v2\/posts\/31882\/revisions\/31958"}],"wp:attachment":[{"href":"https:\/\/einvestingforbeginners.com\/wp-json\/wp\/v2\/media?parent=31882"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/einvestingforbeginners.com\/wp-json\/wp\/v2\/categories?post=31882"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/einvestingforbeginners.com\/wp-json\/wp\/v2\/tags?post=31882"},{"taxonomy":"yst_prominent_words","embeddable":true,"href":"https:\/\/einvestingforbeginners.com\/wp-json\/wp\/v2\/yst_prominent_words?post=31882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}